Telix Brand Guidelines: Melbourne’s 2015 Theranostics Firm Behind Illuccix & Pixclara

An imaging veteran and a Dresden company.

Telix Pharmaceuticals was founded in 2015 by Christian Behrenbruch and Andreas Kluge, BioSpectrum Asia reported in January 2025, when it named Behrenbruch its businessperson of the year for 2024. The aim, the magazine said, was to create “a truly integrated radiopharmaceutical company.” Behrenbruch had worked in medical imaging for about two decades before that, it said, including as president of CTI Molecular Imaging, later part of Siemens, and as chief executive of the antibody company ImaginAb from 2007 to 2015.

Germany was part of the company early on. In early 2017, Biotech Daily reported in July 2025, Telix acquired Therapeia, a radiopharmaceutical company in Dresden founded by Kluge. Telix listed on the Australian Securities Exchange in November 2017, and in November 2024 it also listed on the Nasdaq in New York, the same report said. The company has stayed in Melbourne, with its headquarters in North Melbourne, but Biotech Daily noted that most of its commercial activity is in the United States, where its American headquarters is in Fishers, Indiana, Inside INdiana Business reported in December 2021.

Telix builds its story on theranostics, which the company describes as pairing a precision diagnostic with a targeted therapy. The company says it harnesses targeted radiation “to help physicians diagnose, stage, and treat cancer,” and it is organised in four parts: Therapeutics, Precision Medicine, MedTech and Telix Manufacturing Solutions, a network of production sites.

Three imaging approvals, therapies in trials.

The first product was Illuccix, a kit for preparing gallium-68 gozetotide, also called PSMA-11, an imaging agent for PET scans in prostate cancer. The US Food and Drug Administration approved it in December 2021, Applied Radiation Oncology reported on 20 December 2021. The kit lets hospitals and nuclear pharmacies make doses on site, with gallium-68 from a cyclotron or from generators made by companies including Eckert & Ziegler, and Telix said at the time that it would reach US sites through more than 140 nuclear pharmacies under agreements with Cardinal Health and PharmaLogic. By July 2025 Illuccix was approved in 17 countries, among them the United States, Britain, Germany and Australia, Biotech Daily reported; in September 2026 Telix said it was commercially available in 22 countries.

A second prostate kit, Gozellix, also for gallium-68 gozetotide, was approved by the FDA in March 2025, Biotech Daily reported. The third approval was for the brain. On 14 September 2026 Telix announced that the FDA had approved Pixclara (floretyrosine F 18), a PET imaging drug indicated to help tell recurrent or progressive glioma apart from changes caused by treatment, which Telix calls the first FDA-approved FET-PET drug for glioma. The first US patients received doses in October 2026, the company said, with PharmaLogic making and distributing the doses.

The therapies are still in trials. Telix lists three late-stage candidates: TLX591-Tx, built on lutetium-177, for prostate cancer; TLX101-Tx, using iodine-131, for glioblastoma; and TLX250-Tx, also built on lutetium-177, for kidney cancer. The company states that none of them has marketing authorisation in any country.

To make and move its products, Telix has bought infrastructure. Biotech Daily reported that in September 2024 it acquired RLS Radiopharmacies to expand its North American manufacturing and distribution, and that in April 2025 it bought Isotherapeutics, an Austin-based radiochemistry services company, and ARTMS, a Canadian radioisotope producer.

Isotopes and their image.

Radiopharmaceutical companies sell products that most people never see. A dose leaves a production site as a few millilitres in a small glass vial, travels inside a heavy shielded container and is given in a hospital’s nuclear-medicine department. So the industry’s pictures tend to show the places and machines around the product rather than the product itself.

The factory pictures are the most distinctive. Annual reports and websites in this field often show hot cells, the lead-shielded workstations where technicians handle radioactive material through thick windows and manipulator arms, and robotic dispensing systems that fill vials behind glass. Cyclotrons appear as large circular machines in bare concrete rooms, and research reactors are often photographed from above the pool, where the water glows blue around the core.

The second set of pictures comes from the scan itself. PET and SPECT images, usually shown in bright false colour over a grey outline of the body, are the clearest way to show what a tracer is for, and they recur in product pages, investor slides and congress booths. Alongside them sit images of time: couriers, vans and aircraft, because many isotopes decay within hours. Fluorine-18 has a half-life of about 110 minutes and technetium-99m about six hours, so supply chains are drawn as networks of sites and routes.

The trade meets at a small number of congresses, chiefly the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in North America and the congress of the European Association of Nuclear Medicine (EANM) in Europe, where booths, posters and product launches set much of the year’s visual language. This guide records what can be checked about each company’s history and ownership, and marks what rests only on its own word.

An isotope supplier, agreed in 2026.

The largest step is still pending. On 21 September 2026 Telix announced an agreement to acquire ITM, the producer of lutetium-177 based near Munich, and pharmaphorum reported the same day that the deal extended a wave of consolidation among radiopharmaceutical companies. Telix said the deal would deepen its supply of isotopes and add ITM-11, a lutetium-177 candidate for neuroendocrine tumours that had completed a Phase 3 trial. It needs the approval of Telix shareholders, who are due to meet in Melbourne on 1 December 2026, and of regulators; the deal was agreed in September 2026 and was not completed at the time of writing.

Behrenbruch said the merger “positions Telix at the forefront of the consolidation that is occurring as the industry matures,” and that the two companies had worked closely for many years. pharmaphorum reported that Telix shares traded lower on the day of the announcement.

The company’s public identity rests on its corporate name, the theranostics idea and a family of trademarked product names, among them Illuccix, Gozellix and Pixclara, which its website lists as trademarks of Telix Pharmaceuticals and its affiliates. Its stated values are short and plain: “Everyone counts,” “We strive to be extraordinary” and “We act with determination and integrity.” Its website states that it is intended for corporate communication only, not for promotion or advertising.

For a design guide, Telix shows how a young company can carry a corporate name alongside a growing set of product names that each need to stand on their own. Compare ITM, the German isotope maker it agreed to buy, and Clarity, another Australian radiopharmaceutical company. For this guide we use a deep navy, a violet and a soft lilac with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Telix’s identity on hand — save it to a board in the Made Good inspiration library.